Initial Management and Follow-Up for GAD and Panic Disorder
Use a stepped care model with SSRIs or SNRIs as first-line pharmacotherapy, reserve benzodiazepines only for time-limited use due to risks of dependence and cognitive impairment, and implement monthly monitoring until symptom resolution with gradual benzodiazepine tapering when discontinuing. 1
Initial Assessment and Screening
Screen using validated tools:
- Use the GAD-7 scale for generalized anxiety disorder screening 2
- Screen at initial visit, at regular intervals during treatment, and with any disease status changes 2
- Assess for panic disorder using validated screening questionnaires 3
Rule out medical causes first:
- Exclude uncontrolled medical symptoms (pain, fatigue)
- Rule out delirium (infection, electrolyte imbalances)
- Assess for substance-induced anxiety 1, 2
Determine severity and functional impairment:
- Current symptom level and DSM-V diagnosis presence
- Functional impairment in major life areas (home, work, relationships)
- Chronicity and response to previous treatments
- Risk factors and comorbidities (especially depression) 1
First-Line Pharmacological Treatment
SSRIs are the preferred first-line agents 4, 3, 5:
- Sertraline or escitalopram are preferred SSRIs in adults 6
- Paroxetine, escitalopram, and fluvoxamine have evidence for both GAD and panic disorder 4, 7
- SNRIs (venlafaxine, duloxetine) are equally effective alternatives 5, 8
Benzodiazepine guidance - critical limitations:
- Benzodiazepines should be time-limited only due to increased risk of abuse, dependence, and cognitive impairment 1
- Not recommended for first-line or long-term use due to adverse reactions and higher mortality 3
- May be used briefly for acute symptom control while waiting for antidepressant onset 9
- If used, clonazepam has evidence for panic disorder but requires careful monitoring 10, 7
Psychotherapy Integration
Combine with evidence-based psychotherapy:
- Cognitive behavioral therapy (CBT) is first-line psychological intervention 4, 11
- Individual face-to-face format preferred by most patients 11
- Use treatment manuals of empirically supported treatments 1
- Psychotherapy enhances antidepressant response, particularly in younger patients 5
Follow-Up Schedule and Monitoring
Monthly assessment until symptoms subside 1:
At each visit, assess:
- Compliance with pharmacologic treatment
- Patient concerns about adverse effects
- Satisfaction with symptom relief
- Follow-through with psychological/psychosocial referrals
- Functional improvement in major life areas
After 8 weeks of treatment:
- If inadequate symptom reduction despite good compliance, alter treatment:
- Add psychological or pharmacologic intervention
- Change to different medication within same class or different class
- Consider augmentation strategies 1
Benzodiazepine Tapering Protocol
When to taper:
- Symptoms are under control
- Primary environmental sources of anxiety are no longer present
- Patient has been stable on treatment 1
Tapering approach for clonazepam (based on high-quality evidence) 10:
- Decrease by 0.5 mg per 2-week period until reaching 1 mg/day
- Then decrease by 0.25 mg per week below 1 mg/day
- Longer tapering periods are necessary for potent or rapidly eliminated benzodiazepines 1
- Expect mild withdrawal symptoms: anxiety, tremor, nausea, insomnia, sweating, tachycardia, headache 10
- Most patients (68.9%) can successfully discontinue over 4 months; some require up to 7 months 10
Common pitfall: Tapering too rapidly increases withdrawal symptoms and relapse risk. The evidence clearly shows that gradual reduction (0.25 mg/week for lower doses) minimizes discontinuation symptoms 10.
Treatment Resistance Management
If first SSRI/SNRI fails:
If second trial inadequate:
- Consider pregabalin/gabapentin 6, 8
- Buspirone (particularly if avoiding sexual side effects) 6
- Lavender oil or agomelatine (emerging evidence) 6, 8
If third option fails:
Patient Education and Support
Provide at each visit:
- Education about anxiety disorder and treatment expectations
- Information on which symptoms warrant immediate contact
- Discussion of potential adverse effects and benefits
- Reassurance that pain/symptoms will be treated and patient will not be abandoned 1
Address common barrier: Patients with anxiety often avoid follow-through on referrals due to avoidance behavior—proactively assess compliance and construct plans to circumvent obstacles 1.